Amryt Pharma PLC’s (LON:AMYT) Lojuxta Homozygous Familial Hypercholesterolaemia (HoFH) treatment is to be made available to NHS patients in England.
HoFH is a rare life-threatening disorder that causes abnormally high levels of low density lipoprotein (LDL) cholesterol.
Clinical trials showed Lojuxta can reduce the production and uptake of this ‘bad’ cholesterol, helping sufferers to get their cholesterol levels down to acceptable levels.
Amryt expects the treatment to be available to HoFH patients treated by NHS England during the fourth quarter of 2018.
“We are delighted that NHS England has recognised the significant unmet need in the current treatment of HoFH in England and the potential Lojuxta has to significantly improve the lives of HoFH patients,” said chief executive Joe Wiley.
“This decision today is in line with our strategy to make Lojuxta available to more patients across Amryt's territories and it is estimated that funding approval will have a positive impact on revenue from 2019 and beyond.”